← Back to Screener
LB Pharmaceuticals Inc Common Stock (LBRX)
Price$28.28
Favorite Metrics
Price vs S&P 500 (26W)89.63%
Price vs S&P 500 (4W)16.74%
Market Capitalization$835.01M
All Metrics
Book Value / Share (Quarterly)$11.91
Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)28.18%
EPS (TTM)$-1.05
10-Day Avg Trading Volume0.36M
EPS Excl Extra (TTM)$-1.05
EPS (Annual)$-1.00
ROI (Annual)-8.37%
Cash / Share (Quarterly)$11.67
ROA (Last FY)-8.05%
EBITD / Share (TTM)$-1.24
Cash Flow / Share (Annual)$-1.39
P/B Ratio2.77x
P/B Ratio (Quarterly)1.87x
Net Income / Employee (Annual)$-2
EPS Incl Extra (Annual)$-1.00
Current Ratio (Annual)41.44x
Quick Ratio (Quarterly)39.67x
3-Month Avg Trading Volume0.31M
Revenue / Employee (TTM)$0
52-Week High$29.74
EPS Excl Extra (Annual)$-1.00
26-Week Price Return93.62%
Quick Ratio (Annual)39.67x
13-Week Price Return53.02%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)41.44x
Enterprise Value$584.838
Revenue / Employee (Annual)$0
Cash / Share (Annual)$11.67
3-Month Return Std Dev68.58%
Net Income / Employee (TTM)$-2
ROE (Last FY)-8.37%
EPS Basic Excl Extra (Annual)$-1.00
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.05
Revenue / Share (Annual)$0.00
Year-to-Date Return30.82%
5-Day Price Return10.76%
EPS Normalized (Annual)$-1.00
Month-to-Date Return18.09%
EBITD / Share (Annual)$-1.19
EPS Basic Excl Extra (TTM)$-1.05
P/B Ratio (Annual)1.87x
Book Value / Share (Annual)$11.91
Price vs S&P 500 (13W)52.33%
Beta0.81x
Revenue / Share (TTM)$0.00
52-Week Low$13.36
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.33
4.30
4.30
4.30
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | — | — | — | — | $28.28 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric disorders including schizophrenia and bipolar depression. Its lead candidate, LB-102, is a novel benzamide antipsychotic with the potential to be the first of its kind approved in the United States, based on amisulpride, an antipsychotic already approved in over 50 countries.